Oncology
ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad
In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto
Oncology
ASCO 2026: All about DNA damage response, with Luke Piggot
Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Patients
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Oncology
ASCO 2026: Three ADC approvals in five days, with Ken Keller...
At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
